secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcturus Therapeutics Holdings Inc. (ARCT)
CIK:        0001768224
Form:       8-K
Filed at:   2026-09-23T20:11:34+00:00
Accession:  0001193805-26-001277
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcturus reports positive ARCT-810 Phase 2 data, unveils LUNAR 2.0 platform, to acquire myNEO
--------------------------------------------------------------------------------

- ARCT-810 generally safe; reduced/maintained fasting ammonia and glutamine in OTC deficiency patients.
- LUNAR 2.0 shows 40-fold higher hEPO and 38-fold higher hOTC expression vs LUNAR 1.0 in NHP studies.
- FDA feedback supports ARCT-2601 integration into ongoing Phase 2 study by year-end 2026.
- Definitive agreement to acquire myNEO; closing expected in October 2026.
- New programs for PKU and Gout announced using LUNAR 2.0.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768224/000119380526001277/0001193805-26-001277-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768224/000119380526001277/e665798_8k-arct.htm
  HTML page:      https://secwatch.observer/filing/0001193805-26-001277

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer